Pediatric Migraine
Migraine is the most common cause of recurrent headache in children and adolescents, affecting 5-10% of school-age children. Pediatric migraine differs from adult migraine in several ways: attacks are shorter, often bilateral (rather than unilateral), and prominently feature nausea, vomiting, and photophobia. The CHAMP trial fundamentally changed the field by showing that amitriptyline and topiramate are no better than placebo for pediatric migraine prevention — shifting focus toward non-pharmacologic and lifestyle interventions.
Bottom Line
- Prevalence: 5-10% of school-age children; equal sex ratio before puberty, then 3:1 female predominance after menarche
- ICHD-3 differences: Attacks may be as short as 2 hours (vs 4 hours in adults), often bilateral, and GI symptoms predominate
- Acute: Ibuprofen 10 mg/kg is first-line; sumatriptan nasal spray is FDA-approved for ≥12 years
- CHAMP trial (2017): Neither amitriptyline nor topiramate was superior to placebo for prevention in children/adolescents. High placebo response rate (~61%)
- Prevention priority: Lifestyle modification (sleep, hydration, screen time, stress management) and cognitive behavioral therapy first. Pharmacotherapy reserved for high-frequency migraine after non-drug strategies fail.
- CGRP therapies: Erenumab approved for ≥12 years; galcanezumab approved ≥6 years (based on REBUILD trial)
Clinical Features
| Feature | Pediatric Migraine | Adult Migraine |
|---|---|---|
| Attack duration | 2-72 hours | 4-72 hours |
| Location | Often bilateral (frontal or temporal) | Usually unilateral |
| Quality | May be poorly described; often pressing rather than pulsating in young children | Pulsating/throbbing typical |
| GI symptoms | Prominent — nausea, vomiting, abdominal pain may dominate the presentation | Present but less prominent |
| Photophobia/phonophobia | May be inferred from behavior (retreating to dark room) rather than reported | Usually self-reported |
| Associated features | Pallor, periorbital darkening ("allergic shiners"), motion sensitivity, sleep resolves attack | Less prominent |
| Aura | Less common (~15%); visual aura may be difficult for children to describe | ~25-30% |
Childhood Periodic Syndromes (Migraine Precursors)
- Cyclical vomiting syndrome: Recurrent stereotyped episodes of intense nausea/vomiting lasting hours to days, with complete wellness between episodes. Strong association with future migraine development.
- Abdominal migraine: Recurrent episodes of midline abdominal pain lasting 2-72 hours with nausea, vomiting, and pallor. ICHD-3 diagnosis.
- Benign paroxysmal vertigo of childhood: Brief episodes of vertigo with nystagmus in preschool children. Precursor to migraine with or without vestibular migraine.
- Benign paroxysmal torticollis: Recurrent episodes of head tilt in infants. Associated with CACNA1A mutations and later migraine.
Acute Treatment
| Agent | Dose | Evidence / Approval | Notes |
|---|---|---|---|
| Ibuprofen | 10 mg/kg (max 400-600 mg) | First-line. Hämäläinen et al. (1997): superior to placebo and equivalent to acetaminophen for pain relief | Best data among acute medications. Treat early. Liquid formulation for young children. |
| Acetaminophen | 15 mg/kg (max 1000 mg) | Effective; slightly less than ibuprofen in head-to-head | Alternative first-line; safe profile |
| Sumatriptan nasal spray | 5-20 mg | FDA-approved ≥12 years. Winner et al. (2006): positive RCT | Nasal spray preferred over oral in children (rapid onset, useful when nauseous). Bitter taste may limit adherence. |
| Zolmitriptan nasal spray | 2.5-5 mg | FDA-approved ≥12 years. Positive pediatric RCT. | Better taste than sumatriptan nasal; good tolerability |
| Rizatriptan | 5 mg (<40 kg) or 10 mg (≥40 kg) | FDA-approved ≥6 years. Positive RCT in ages 6-17 | ODT formulation useful in children who cannot swallow tablets |
| Almotriptan | 6.25-12.5 mg | FDA-approved ≥12 years | Well-tolerated oral option |
| Nerivio (REN) | 45-minute session | FDA-cleared ≥12 years for acute migraine | Non-drug option; smartphone-controlled armband. Positive open-label data in adolescents. |
Acute Treatment Principles in Children
- Treat early: Pediatric attacks escalate quickly. Ibuprofen at first sign of migraine is the most effective strategy.
- School plan: Ensure the child has access to medication at school (nurse's office). Delays in treatment are a major cause of treatment failure in school-age children.
- Rest and sleep: Many pediatric attacks resolve with sleep. Allow the child to rest in a dark, quiet room when possible.
- Avoid frequent use: MOH can develop in children, though less studied. Limit acute medication to <10 days/month.
Prevention
The CHAMP Trial (Powers 2017)
The landmark trial that reshaped pediatric migraine prevention:
- Design: 361 children and adolescents (ages 8-17) with ≥4 migraine days/month randomized to amitriptyline (1 mg/kg/day), topiramate (2 mg/kg/day), or placebo for 24 weeks
- Primary outcome: ≥50% reduction in headache days
- Results:
- Amitriptyline: 52% responder rate
- Topiramate: 55% responder rate
- Placebo: 61% responder rate
- Trial stopped early for futility — neither drug was better than placebo
- Side effects were significant: Fatigue/mood changes (amitriptyline), cognitive/weight effects (topiramate) vs minimal side effects in placebo group
- The high placebo response rate in children underscores the importance of non-specific therapeutic effects (regular clinic visits, headache diaries, lifestyle counseling, expectation)
Non-Pharmacologic Prevention (First-Line)
Lifestyle and Behavioral Interventions
- Cognitive behavioral therapy (CBT): The CHAMP trial included CBT elements in all arms. Powers et al. (2013) showed CBT + amitriptyline superior to headache education + amitriptyline. CBT alone may account for much of the "placebo" effect in CHAMP.
- Sleep regulation: Consistent bed/wake times. Address screen time before bed. Many pediatric migraineurs have disordered sleep.
- Hydration: Children often under-hydrate, especially at school. Target 6-8 glasses of water/day.
- Regular meals: Skipping breakfast is a common trigger. Three meals + snacks.
- Exercise: Regular aerobic exercise (30 minutes, 3-5x/week) reduces migraine frequency in adolescents.
- Screen time management: Prolonged screen use is a modifiable trigger in many pediatric patients.
- Stress management: School-related stress, bullying, and academic pressure are common triggers. Address proactively.
- Biofeedback: Effective in children ≥8 years. Level A evidence for migraine prevention.
Pharmacologic Prevention
Given CHAMP results, pharmacologic prevention is reserved for children with high-frequency migraine (≥8 days/month) who have not responded to lifestyle and behavioral interventions.
| Agent | Dose | Evidence | Notes |
|---|---|---|---|
| Amitriptyline | 0.25-1 mg/kg at bedtime | Negative in CHAMP; positive in older, smaller trials. May benefit when combined with CBT. | Best if comorbid insomnia or tension-type headache overlap. ECG in patients with cardiac risk. |
| Topiramate | 1-2 mg/kg/day (max 100 mg) | Negative in CHAMP; positive in earlier RCTs at higher doses. FDA-approved ≥12 years for migraine prevention. | Cognitive side effects limit use in students. Weight loss may be beneficial or harmful depending on patient. |
| Propranolol | 1-2 mg/kg/day divided BID-TID | Conflicting evidence (some positive RCTs, some negative). Used in practice. | Avoid in asthma. Monitor heart rate and exercise tolerance in athletes. |
| Cyproheptadine | 2-8 mg at bedtime | Limited evidence; commonly used in children <6 years (off-label) | Antihistamine/antiserotonergic. Sedation and appetite stimulation (may be beneficial in underweight children). |
| Galcanezumab | 120 mg SC monthly (≥30 kg) | REBUILD trial (Szperka 2024): positive in ages 6-17. FDA-approved ≥6 years. | First CGRP mAb with pediatric approval. Monthly injection; well-tolerated. |
| Erenumab | 70 mg SC monthly | FDA-approved ≥12 years based on pediatric extension data | Monthly autoinjector |
| Nutraceuticals | Magnesium 9 mg/kg/day; Riboflavin 200-400 mg/day; CoQ10 1-3 mg/kg/day | Limited but positive small studies for each | Low risk; reasonable first-line adjuncts. Often used before prescription medications. |
When to Image
- Not routinely needed for children meeting ICHD-3 migraine criteria with normal neurologic examination
- Indications for imaging: Abnormal neurologic exam, new-onset worst headache, progressive worsening pattern, headache awakening from sleep consistently, age <6 with recurrent headache, personality or behavioral change, head circumference abnormality
- MRI preferred over CT in children (avoid radiation)
References
- Powers SW, et al. Trial of amitriptyline, topiramate, and placebo for pediatric migraine (CHAMP). N Engl J Med. 2017;376(2):115-124.
- Powers SW, et al. Cognitive behavioral therapy plus amitriptyline for chronic migraine in children and adolescents: a randomized clinical trial. JAMA. 2013;310(24):2622-2630.
- Hershey AD, et al. Pediatric migraine: recognition and treatment. J Am Acad Nurse Pract. 2007;19(10):517-522.
- Szperka CL, et al. Galcanezumab for the prevention of migraine in children and adolescents (REBUILD). Lancet Child Adolesc Health. 2024.
- Winner P, et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics. 2000;106(5):989-997.
- Oskoui M, et al. Practice guideline update: pharmacologic treatment for pediatric migraine prevention. Neurology. 2019;93(11):500-509.